Biotech Values

[RockRat]

Re Paratek:

The only other thing I caught was their website had the NDA for Omadacycline being submitted Q1, '18. Doesn't appear that they've met that deadline.

Not sure what you saw on the website. They began submission of a rolling NDA on time. The concern for Paratek isn't regulatory, it's commercial. For Sarecycline, the pricing versus existing competition is a worry. It certainly won't be first line. For Omadacycline, the worry is combos of existing antibiotics is supposedly the new paradigm, so the ability of Omadacycline to compete and get on formularies is being questioned. If they can get patients out of then hospital sooner, as they hope, they will win that competition, but it may take some time for that to become evident.

I hold a modest position. I don't think there's much downside from here, but upside will likely be slow for a while.

Regards, RockRat